This clinical trial is focused on studying the prevention of migraine in children and adolescents aged 6 to under 18 years. Migraine is a type of headache that can cause severe pain, often accompanied by nausea, vomiting, and sensitivity to light and sound. The treatment being tested in this study is called Rimegepant, which is taken as an oral lyophilisate, a form that dissolves in the mouth. The study will compare the effects of Rimegepant with a placebo to see how well it works in reducing the number of migraine days each month.

The purpose of the study is to evaluate the effectiveness and safety of Rimegepant in preventing migraines. Participants will be randomly assigned to receive either Rimegepant or a placebo. The study will last for several weeks, during which participants will take the medication and report the number of migraine days they experience. The goal is to see if Rimegepant can significantly reduce the frequency of migraines compared to the placebo.

Throughout the study, participants will be monitored to ensure their safety and to gather information on how the treatment affects their quality of life. The study aims to provide valuable insights into whether Rimegepant can be an effective preventive treatment for migraines in young people, potentially offering a new option for managing this challenging condition.